6KK5
Crystal structure of Zika NS2B-NS3 protease with compound 15
Summary for 6KK5
| Entry DOI | 10.2210/pdb6kk5/pdb |
| Descriptor | Serine protease subunit NS2B, NS3 protease, 1-[(5~{S},8~{R},15~{S},18~{S})-15,18-bis(4-azanylbutyl)-5-methyl-4,7,14,17,20-pentakis(oxidanylidene)-3,6,13,16,19-pentazabicyclo[20.3.1]hexacosa-1(25),22(26),23-trien-8-yl]guanidine, ... (4 entities in total) |
| Functional Keywords | viral protease, protease inhibitor complex, viral protein |
| Biological source | Zika virus (ZIKV) More |
| Total number of polymer chains | 2 |
| Total formula weight | 25547.79 |
| Authors | Quek, J.P. (deposition date: 2019-07-23, release date: 2020-06-17, Last modification date: 2024-10-16) |
| Primary citation | Braun, N.J.,Quek, J.P.,Huber, S.,Kouretova, J.,Rogge, D.,Lang-Henkel, H.,Cheong, E.Z.K.,Chew, B.L.A.,Heine, A.,Luo, D.,Steinmetzer, T. Structure-Based Macrocyclization of Substrate Analogue NS2B-NS3 Protease Inhibitors of Zika, West Nile and Dengue viruses. Chemmedchem, 15:1439-1452, 2020 Cited by PubMed Abstract: A series of cyclic active-site-directed inhibitors of the NS2B-NS3 proteases from Zika (ZIKV), West Nile (WNV), and dengue-4 (DENV4) viruses has been designed. The most potent compounds contain a reversely incorporated d-lysine residue in the P1 position. Its side chain is connected to the P2 backbone, its α-amino group is converted into a guanidine to interact with the conserved Asp129 side chain in the S1 pocket, and its C terminus is connected to the P3 residue via different linker segments. The most potent compounds inhibit the ZIKV protease with K values <5 nM. Crystal structures of seven ZIKV protease inhibitor complexes were determined to support the inhibitor design. All the cyclic compounds possess high selectivity against trypsin-like serine proteases and furin-like proprotein convertases. Both WNV and DENV4 proteases are inhibited less efficiently. Nonetheless, similar structure-activity relationships were observed for these enzymes, thus suggesting their potential application as pan-flaviviral protease inhibitors. PubMed: 32501637DOI: 10.1002/cmdc.202000237 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.03 Å) |
Structure validation
Download full validation report






